Authors’ conclusions: palivizumab did not provide any discernible long-term protective effect. In adolescent survivors of extreme prematurity good clinical and physiological respiratory outcomes were shown, as well as improvement with respect to preschool age. The forced expiratory volume in the first second (FEV1) remained lower than in healthy subjects, although within the normal range.
Reviewers’ commentary: within its possible limitations, this study did not find any relevant clinical differences in adolescence between preterm infants who received palivizumab compared to those who did not. This data adds to the existing controversy regarding its use due to the high cost of the drug in relation to the benefits, which, according to the results of this study, do not seem to extend beyond school age.